Rhofade, Oxymetazoline Cream 1% for the redness of Rosacea

Rhofade is Allergan’s Oxymetazoline based topical treatment for the red face of rosacea. Rhofade is known chemically as a Selective α1-Adrenergic Receptor Agonist, and during the drug’s development was known as AGN-199201 and also V-101.

Recent Rosacea Blog Posts

Aclaris are the new owners of Rhofade

News today that the previous owners of the intellectual property that spawned the product we know as Rhofade, have purchased the rights to buy it back from Allergan. So those responsible for creating the company that originally created the oxymetazoline based topical, and then sold it to Allergan in 2011 are now purchasing the product […]

Continue Reading

Rhofade good for at least a year and gentler than Mirvaso

If you decide to try Allergan’s topical for redness – Rhofade, is it likely to work for you, and how long should you expect it to continue to work for you? Well, a year long study of users of Rhofade has found that the vast majority continued to enjoy ongoing significant relief from their facial […]

Continue Reading

Rhofade vs. Mirvaso – trial them before you leave the surgery

  When faced with the prospect of paying $570 for a 30gm tube of Rhofade or $494 for a 30gm tube of Mirvaso, these authors suggest that you can save 15% straight up by asking to compare them before you even leave the doctor’s surgery. The 15% saving comes from going away being happy that […]

Continue Reading

Mirvaso and Rhofade are very different indeed

Some laboratory based research has for the first time given us a highly detailed view of the method of action of 2 recently approved treatments for the redness of rosacea. The two treatments, brimonidine based Mirvaso, and oxymetazoline based Rhofade have been shown by this research to differ in their method of action. Although brimonidine […]

Continue Reading

Rhofade may come with a heart valve damage risk

A recently published paper that seeks to compare the actions of oxymetazoline (Rhofade) and brimonidine (Mirvaso) has raised a possible safety issue with the action of oxymetazoline. The paper states the safety issue as; As the 5-HT2B receptor is potentially involved in drug-induced valvulopathy, the benefit/risk ratio (of Rhofade ed.) should be carefully considered, especially in […]

Continue Reading

 

Top